CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
LAT8881 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03865953
NCT03865953Phase 2Completed
CompareCT.gov

A Phase IIa Study of the Efficacy and Safety of Oral LAT8881 in Neuropathic Pain

Lateral Pharma Pty Ltd·interventional·Posted Mar 7, 2019·Updated Jun 14, 2021

In Brief

A Phase 2 clinical trial evaluating LAT8881 and Placebo for Neuropathic Pain and 2 related conditions. Completed, enrolled 53 participants across 6 sites in 2 countries.

Detailed Summary

This is a randomised, placebo-controlled, double-blind, crossover, phase IIa study to investigate the efficacy and safety of oral LAT8881 in neuropathic pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeuropathic Pain, Diabetic Peripheral Neuropathy (DPN), Post Herpetic Neuralgia (PHN)
CountriesAustralia, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMar 7, 2019
Enrollment StartApr 9, 2019
Primary CompletionApr 19, 2020
Study CompletionMay 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 7.3 years ago

Interventions

LAT8881drug

LAT8881 oral capsule

Placebodrug

Placebo oral capsule